Loading clinical trials...
Loading clinical trials...
This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
H. Lundbeck A/S
NCT02361554 · Treatment-resistant Schizophrenia
NCT05074732 · Schizophrenia, Forensic Psychiatry, and more
NCT06060886 · Schizophrenia, Treatment-resistant Schizophrenia, and more
NCT03868839 · Schizophrenia, Schizo Affective Disorder, and more
NCT04528095 · Treatment-resistant Schizophrenia
University of California San Diego Health System
San Diego, California
Emory University Cognitive Neurology Clinic & ADRC
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions